SPY Gains, Longer-Term Plays on the Move

SPY Gains, Longer-Term Plays Popping: 

In terms of our options trading ideas from yesterday morning’s premarket report, we saw rather unimpressive performances from a couple of our ideas. However, our laser-like accuracy in dealing with the SPY continued in spades with the SPY 05/11 $402-404 Calls, so we’ve got the figures on those for you this morning.

We will also circle back around to a couple of the longer-term sets of ideas we made last week which have made some very impressive moves for us so far, and don’t expire until the end of next week. We signaled possible plays in the EL 05/20 $250-230 Puts and the FTNT 05/20 $290-310 Calls on Tuesday and Thursday, respectively, and each of them has produced major moves, which were as follows:

SPY 05/11 $402-404 Calls
 1.64-4.81 (+193%)
$403: 1.40-4.25 (+204%)
$404: 1.20-3.75 (+213%)

EL 05/20 $250-230 Puts
$250: 5.29-22.87 (+332%)
$240: 2.75-13.84 (+403%)
$230: 1.45-8.50  (+486%)

FTNT 05/20 $290-310 Calls
 1.15-4.60 (+300%)
$300: .75-2.75 (+267%)
$310: .45-1.45 (+222%)

Fresh Options Ideas:
EA Weekly $111-113 Calls
ALC Weekly 05/20 $65-70 Calls
COIN Weekly $65-55 Puts 

Extended Watchlist:

Huge Options, OTC Gainers & More

Big-Time Options Winners:

We put forth a pair of options ideas in yesterday morning’s premarket report. One on the bullish side of things and one bearish. They both did exactly what we needed them to do, and produced for us several incredible intraday gain chances.

Our contracts of interest for the day were the SE Weekly $295-302.50 Calls and the HD Weekly $327.50-322.50 Puts, and in both cases, we had the opportunity to score some major multi-bag gains on the day.

Here were the total moves and possible single session profits on those plays:

SE Weekly $295-302.50 Calls
$295: 5.50-23.95 (+335%)
$297.50: 4.30-20.34 (+373%)
$300: 3.50-19.62 (+461%)
$302.50: 3.10-16.50 (+432%)

HD Weekly $327.50-322.50 Puts
$327.50: 5.30-11.27 (+113%)
$325: 3.82-8.92 (+134%)
$322.50: 2.81-7.20 (+156%)

Fresh Options Ideas: 
WB Weekly $47-49 Calls
TJX Weekly $70-71 Calls
LOW Weekly $187.50-190 Calls
ALC Weekly $75-80 Calls 

AXP Energy Ltd. AUNXF – Recap:

We also had one of the symbols from yesterday’s extended watchlist blow its own lid, and pop off for a serious intraday move. AUNXF traded from a low of .0078 and went on to hit .0179. That works out to a 129% run on the day, providing a great example of why readers shouldn’t just gloss over our daily extended watchlists!

The stock closed very close to its daily highs, so keep an eye peeled for the possibility of further opportunities here.

Extended Watchlist:

MAR Puts, BSGM Updates

Marriot International, Inc. MAR – Update

The markets took a late dive yesterday afternoon, and as they plunged, it helped our bearish idea on MAR realize some nice new gains. We were just reporting on the MAR Weekly $86.50-85 Puts in yesterday’s report, with what were only nominal gains at the time. Today the figures are looking far more impressive.

Even after the company’s CEO somewhat brashly called MAR stock ‘a bottom’, traders did not agree as it took a considerable hit and headed lower. That produced the following opportunities in our targeted puts;

MAR Weekly $86.50-85 Puts
2.80-7.00 (+150%)
$86:2.70-6.60 (+144%)
$85.50: 2.20-5.02 (+128%)
$85: 2.13-5.97 (+180%)

Fresh Options Ideas: 
ALC Weekly $55-57.50 Calls
PGTI Weekly $10 Calls
CYBR Weekly $107-104 Puts

BioSig Technologies, Inc. BSGM

We have been tracking BSGM pretty closely this spring, and the stock has put together an incredible performance. Subsequent to our alert of this play roughly 5 weeks ago on April 7th, it registered a low of 3.45/share. The company has been doing trials for potential coronavirus treatments with the drugs Merimepodib and Remdesivir.

After stacking gains on top of gains and essentially going up continuously with very few daily exceptions, BSGM arrived at a new high of 12.43 yesterday. That represents an increase of 260% in just over a month’s time!

We will certainly continue to track BSGM’s progress and keep our ears to the track for any further developments in the company’s quest for a viable COVID-19 treatment.

Extended Watchlist: